Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Short-term Investments (2019 - 2025)

Historic Short-term Investments for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $392.7 million.

  • Kymera Therapeutics' Short-term Investments fell 1059.05% to $392.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $392.7 million, marking a year-over-year decrease of 1059.05%. This contributed to the annual value of $368.5 million for FY2024, which is 3909.67% up from last year.
  • Latest data reveals that Kymera Therapeutics reported Short-term Investments of $392.7 million as of Q3 2025, which was down 1059.05% from $329.6 million recorded in Q2 2025.
  • Over the past 5 years, Kymera Therapeutics' Short-term Investments peaked at $442.3 million during Q2 2024, and registered a low of $264.9 million during Q4 2023.
  • Moreover, its 5-year median value for Short-term Investments was $346.7 million (2023), whereas its average is $351.2 million.
  • As far as peak fluctuations go, Kymera Therapeutics' Short-term Investments skyrocketed by 5870.42% in 2024, and later crashed by 2548.08% in 2025.
  • Kymera Therapeutics' Short-term Investments (Quarter) stood at $394.4 million in 2021, then decreased by 14.11% to $338.8 million in 2022, then dropped by 21.8% to $264.9 million in 2023, then soared by 39.1% to $368.5 million in 2024, then grew by 6.58% to $392.7 million in 2025.
  • Its Short-term Investments stands at $392.7 million for Q3 2025, versus $329.6 million for Q2 2025 and $373.2 million for Q1 2025.